REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or...

Related Keywords

Brazil ,Rockville ,Maryland ,United States ,United Kingdom ,Dana Cormack ,Chris Brinzey ,Ultragenyx Pharmaceutical Inc ,Technology Platform ,Technology Platform Licensees ,Rocket Pharmaceuticals Inc ,Nasdaq ,United Kingdom Health Authority ,Technology Licensee Program ,Development Expenses ,Exchange Commission ,Corporate Communications ,Securities Exchange ,Manufacturing Innovation Center ,Chief Executive Officer ,Hunter Syndrome ,Innovation Center ,Biologics License Application ,Long Term Follow Up ,Duchenne Muscular Dystrophy ,Mucopolysaccharidosis Type ,Licensee Program Highlights ,Rocket Pharmaceuticals ,Ultragenyx Pharmaceutical ,Ornithine Transcarbamylase ,Administrative Expenses ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Tax Benefit ,Comprehensive Income ,Regenxbio Inc ,